Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 1/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9797611 | 0.83 | SLC7A5 (0.46) | ANPEPLAP3 | |
| SCHEMBL2171977 | 0.82 | ANPEP (0.40) | ANPEPLAP3GABRR1ENPEP | |
| SCHEMBL4326971 | 0.80 | LAP3 (0.49) | ANPEPLAP3GABRR1LTA4H | |
| SCHEMBL338962 | 0.80 | ANPEP (0.39) | ANPEPLAP3GABRR1 | |
| SCHEMBL9697359 | 0.79 | ANPEP (0.56) | ANPEPLAP3 | |
| SCHEMBL9697205 | 0.78 | ANPEP (0.35) | ANPEPLAP3ENPEPLTA4H | |
| SCHEMBL2171773 | 0.77 | ANPEP (0.37) | ANPEPLAP3GABRR1 | |
| SCHEMBL2402598 | 0.77 | GRM3 (0.45) | ANPEPLAP3GABRR1 | |
| SCHEMBL1304832 | 0.77 | FOLH1 (0.48) | GABRR1 | |
| SCHEMBL9697243 | 0.76 | LAP3 (0.77) | ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5143908-A | Carboxylic acids containing amino and phosphinyl groups | MERCK & CO., INC. (US) | 1992-09-01 | — | — | US | claimed |
| US-5099063-A | 3-(1-aminoalkylphosphinyl)-(2-substituted)propionic acids | MERCK & CO., INC. (US) | 1992-03-24 | — | — | US | claimed |
| EP-0266978-A2 | Novel antibacterial agents and potentiators of carbapenem antibiotics | MERCK & CO. INC. (US) | 1988-05-11 | — | — | EP | claimed |
| US-8471063-B2 | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-5143908-A | Carboxylic acids containing amino and phosphinyl groups | MERCK & CO., INC. (US) | 1992-09-01 | — | — | US | disclosed |
| US-5099063-A | 3-(1-aminoalkylphosphinyl)-(2-substituted)propionic acids | MERCK & CO., INC. (US) | 1992-03-24 | — | — | US | disclosed |
| EP-0266978-A2 | Novel antibacterial agents and potentiators of carbapenem antibiotics | MERCK & CO. INC. (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4715994-A | PHOSPHINIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1987-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | TGM2, TGM3, TGM1 | ANPEP 237/4885LAP3 125/4885GABRR1 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.